IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
HR+ Breast Cancer
Tianjin Medical University Cancer Institute and Hospitalmonoclonal_antibodyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the HR+ Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Kristina A. Fanucci | Phase 4 | BBB |
Carboplatin Avenzo Therapeutics, Inc. | Phase 3 | BB |
Catequentinib First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
sc-101 Tianjin ConjuStar Biologics Co., Ltd. | Phase 2 | CCC |
Shr-A1811 Tianjin Medical University Cancer Institute and Hospital | Phase 2 | CCC |
ETOPOSIDE Hunan Cancer Hospital | Phase 2 | CCC |
nkt5097 cdk2/cdk4 dual degrader NiKang Therapeutics, Inc. | Phase 1 | CC |
cirtociclib Blueprint Medicines Corporation | Phase 1 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →